related to the allograft rejection. It is known that eosinophilia is a marker for rejection in liver, kidney, and heart transplants. Graft eosinophilia is known to be a sensitive and specific marker of liver rejection. 4 An association between graft eosinophilia as well as peripheral eosinophilia and kidney rejection has been observed. 5 Blood eosinophilia is a marker of cardiac rejection, and the level of eosinophilia correlates with the severity of rejection. 1 In 1992, Yousem 6 reported nine patients with tissue eosinophilia on lung allograft biopsy. Five of these cases were associated with acute rejection, and the other four were associated with infection. Each of the cases associated with rejection resolved with steroids, but one patient later acquired OB. Two of the cases associated with infection, Aspergillus and coxsackie A2 virus, resolved with treatment of the infection; two patients died of their infections.
Bewig et al 7 reported a series of four patients who presented with recurrent eosinophilic alveolitis on BAL. Only one patient underwent a concomitant transbronchial biopsy, and it revealed acute rejection. Each patient responded to treatment with steroids.
Several cases of sarcoidosis and pulmonary eosinophilia or chronic eosinophilic pneumonia occurring concomitantly have been described but not in the posttransplant period. 9 -11 A review of 140 patients with sarcoidosis found 14% had peripheral blood eosinophilia (absolute eosinophil count Ͼ 350/L); however, the authors did not find an increase in parenchymal lung eosinophilia. 12 Both of our patients had peripheral blood eosinophilia and pulmonary eosinophilia. Whether this was due to sarcoidosis, medications, graft rejection, or another etiology is unclear. Although there was no associated rejection on biopsy, perhaps the eosinophilic infiltrates foreshadow a decline in allograft function in patients with sarcoidosis.
In conclusion, we report two cases of acute eosinophilic pneumonia in lung transplant recipients for sarcoidosis. Although the significance of eosinophilic pneumonia is unclear, it is concerning that both patients went on to acquire BOS within a relatively short time period. Eosinophils are known to release inflammatory mediators such as eosinophil chemotactic factor, interleukin 5, and leukotriene B 4 . Further studies may identify a role for these in the predisposition to OB. A higher suspicion for pulmonary eosinophilia in transplanted patients with sarcoidosis is warranted. Perhaps early and aggressive treatment when pulmonary eosinophilia is diagnosed would prevent the development of OB.
Three patients are described who illustrate distinctive patterns of sleep-disordered breathing that we have observed in patients who are receiving longterm, sustained-release opioid medications. Polysomnography shows respiratory disturbances occur predominantly during non-rapid eye movement (NREM) sleep and are characterized by ataxic breathing, central apneas, sustained hypoxemia, and unusually prolonged obstructive "hypopneas" secondary to delayed arousal responses. In contrast to what is usually observed in subjects with obstructive sleep apnea (OSA), oxygen desaturation is more severe and respiratory disturbances are longer during NREM sleep compared to rapid eye movement sleep. Further studies are needed regarding the effects of opioids on respiration during sleep as well as the importance of interaction with other medications and associated risk factors for OSA.
(CHEST 2003; 123:632-639) E ditorials, research studies, and patient surveys have consistently indicated that pain is inadequately treated, and physician education is woefully insufficient. 1 Time-contingent, sustained-release opioids have now become the standard of care for patients with chronic, nonmalignant pain. Although the analgesic and respiratory depressant effects of -opioid receptor agonists are well known, 2,3 the potential adverse respiratory consequences with long-term oral therapy are considered minimal:
It is now accepted by practitioners of the specialty of pain medicine that respiratory depression induced by opioids tends to be a short-lived phenomenon, generally occurs only in the opioid-naive patient, and is antagonized by pain. Therefore, withholding the appropriate use of opioids from a patient who is experiencing pain on the basis of respiratory concerns is unwarranted. 4 The scientific basis for the assertion that long-term use of sustained-release opioids is safe is limited by the paucity of studies, particularly in persons who may be more susceptible to the respiratory depressant effects of opioids during sleep. Sleep may be associated with increased upper airway resistance, obstructive sleep apnea (OSA) syndrome, alveolar hypoventilation, and central apnea including Cheyne-Stokes breathing pattern. [5] [6] [7] [8] Restoration of ventilation and prevention of asphyxia is dependent on the interaction of peripheral chemoreceptors (carotid body) mediated through the carotid sinus nerve, mechanoreceptors in the chest wall and lungs mediated through the vagus nerve, and central respiratory controllers located in the brainstem. 9, 10 The carotid bodies appear to be responsible for immediate breath-by-breath dynamic control, while the central brainstem controllers establish the baseline minute ventilation and respond relatively slowly to changes in carbon dioxide levels. 10 In all cases of sleep-disordered breathing, the control of breathing may be compromised by medications such as alcohol, sedatives, hypnotics, and opioids. 11 We have observed numerous patients in whom we believe that opioid therapy not only contributed to the pathogenesis of their sleep-disordered breathing but also complicated therapy. If true, then there is currently a significant risk for many patients because of the concurrent increasing use of long-acting opioids coupled with the high prevalence of underdiagnosed sleep-disordered breathing. The following three cases illustrate distinctive patterns of abnormal breathing that seem to be associated with long-term opioid therapy.
Materials and Methods
The patients in this report were selected from our clinic and had been referred for evaluation of OSA. All three patients completed detailed sleep questionnaires and were examined by a pulmonologist certified by the American Academy of Sleep Medicine. Each patient was studied with attended polysomnography (Cadwell Easy II Sleep, software version 1.5; Cadwell Laboratories; Kennewick, WA). In addition to the initial polysomnogram, each was retested with nasal continuous positive airway pressure (CPAP) titration using a standard protocol for the laboratory. Electrophysiologic sleep parameters included the following: central (C3/A2 or C4/A1) and occipital (O1/A2 or O2/A1) EEG, right and left electrooculogram, and submentalis electromyogram. Periodic limb movements were monitored by anterior tibialis electromyogram, and single-lead ECG was recorded. Airflow was detected by nasal pressure transducers, and respiratory effort was determined by measurement of chest and abdomen motion using pneumatic bands. Arterial oxygen saturation (Sao 2 ) was measured with an Ohmeda 3700 oximeter (Datex-Ohmeda; Madison, WI) set in the fast-response (3-s) mode from the finger, and the Sao 2 was simultaneously recorded on a strip chart at slow speed. Raw data were manually scored in 30-s epochs for sleep stages using standard criteria. 12 Apneas were scored on the basis of Ն 10-s absence of airflow (0 to 20% of baseline signal). Hypopneas were scored when there was a clear reduction of airflow for Ն 10 s associated with either a Ն 3% decrease in Sao 2 or an arousal respectively. 13 Obstructive events were defined by the presence of respiratory effort and/or characteristic flattening of inspiratory airflow pattern. Central apneas were defined by the absence of detectable effort using high-gain amplifier settings. The respiratory disturbance index was computed as the total of all respiratory events divided by the total sleep time in hours. All of the subjects in this report were not cigarette smokers, none had asthma or other clinical pulmonary disease, and all had normal Sao 2 for this elevation while awake (Ն 93%). The results of sleep and respiratory measurements obtained from polysomnography for all three cases are shown in Tables 1 and 2 , respectively.
Case 1
A 35-year-old woman (height, 155 cm; weight, 87 kg; body mass index [BMI], 36; and neck circumference, 39 cm) presented with chronic fatigue; poor sleep quality; generalized discomfort; back, right hip, and feet pain; restless legs syndrome; frequent nocturia; snoring; and witnessed apneas. Previous diagnoses included depression and gastroesophageal reflux. Medications included the following: hydrocodone, 7.5 mg tid; time-release morphine sulfate, 15 mg bid; tramadol, 50 mg at bedtime; sertraline; nefazadone; amitriptyline; alprazolam, 0.5 mg; celecoxib; and omeprazole. Baseline polysomnography revealed obstructive respiratory disturbances that were most severe during non-rapid eye movement (NREM) sleep (Fig 1, top, A) . Many events defied ordinary classification and were characterized by unusually prolonged obstructive hypoventilatory periods each lasting 5 to 8 min and associated with gradually progressive severe hypoxemia to 78 to 80% (Fig  1, center, B) . The inspiratory airflow pattern using a nasal air pressure transducer was consistent with increased upper airway resistance (Fig 1, bottom, C) . The respiratory rate and qualitative tidal volume did not change over these periods but were finally reversed with one or two deeper breaths. The patient ingested a second dose of hydrocodone (7.5 
Case 2
A 43-year-old woman (height, 160 cm; weight, 66 kg; BMI, 26; and neck circumference, 32 cm) presented with chronic fatigue, excessive sleepiness, and snoring. Previous diagnoses included depression, hypertension, and gastroesophageal reflux. Opioids had been prescribed for complex regional pain syndrome, chro-nic low back and severe unremitting leg pain. Medications included methadone, 40 mg/d; fentanyl, 50 g/h patch every 72 h; nefazadone; quetiapine; bupropion; lisinopril; and famotidine. Baseline polysomnography showed severe hypoxemia and frequent irregular respiratory disturbances almost exclusively during NREM sleep (Fig 2, top, A) . Analogous to atrial fibrillation, the ventilatory pattern was ataxic, consistent with Biot breathing (Fig 2, center, B) , and continued although hypoxemia was corrected with supplemental oxygen (Fig 2, bottom, C) . The Sao 2 varied erratically, and hypoxemia to 76% was observed associated with prolonged obstructive hypoventilatory periods similar to case 1. Oxygen administration during the last part of the study corrected the Sao 2 to 98%, but erratic tidal volumes, irregular respiratory rate, and central apneas continued. Because repeat polysomnography with nasal CPAP was only partially effective, both CPAP and oxygen were prescribed.
Case 3
A 52-year-old woman (height, 160 cm; weight, 127 kg; BMI, 51; and neck circumference, 45 cm) presented with a 6-year history of chronic fatigue, involuntarily falling asleep during the day, loud snoring, and witnessed apneas. Previous diagnoses included chronic fatigue syndrome, hypertension, depression, hypothyroidism, and noninsulin-dependent diabetes. Medications included glyburide, furosemide, potassium chloride, buspirone, and fluoxetine. Previous polysomnography (September 1995) using a split-night protocol had confirmed the presence of hypoxemia, and frequent obstructive apneas were corrected with nasal CPAP of 10 cm H 2 O. Beginning in March 2000, she was treated with gabapentin; time-release morphine sulfate, 45 mg bid; and hydrocodone, 7.5 mg, as needed for diabetic neuropathy and Charcot foot disease. The morphine sulfate was increased to 40 mg tid in June 2000 and was subsequently changed to methadone, 10 mg bid, in October 2000. Except for obesity and Charcot foot disease, general and neurologic examinations including cranial MRI were normal. Because of increasingly profound hypersomnia in spite of nightly use of nasal CPAP, polysomnography was repeated in February 2001 beginning with her previous therapeutic pressure of 10 cm H 2 O and titrated to 16 cm H 2 O. In contrast to her original study, polysomnography showed continuous central apneas and moderate hypoxemia but only during NREM (Fig 3, top, A, and bottom, B) . Increasing the CPAP was well tolerated but was completely ineffective. Oxygen and CPAP were prescribed.
Discussion
These three examples illustrate the types of breathing patterns that we are now recognizing with increasing frequency. In contrast with the typical respiratory abnormalities seen in opioid-free patients with OSA, we have observed the following unique distinguishing features in patients receiving sustained-release opioid medications: (1) apnea duration and severity of hypoxia are more severe during NREM sleep compared to rapid eye movement (REM) sleep; (2) ataxic or Biot breathing pattern 14 characterized by irregular respiratory pauses and gasping without periodicity present during NREM sleep; (3) recurrent and unusually prolonged periods of obstructive hypoventilation lasting at least 5 min resulting in progressive severe hypoxemia and not present during REM sleep; and (4) ineffectiveness of nasal CPAP.
That opioids either contributed to the pathogenesis of sleep-disordered breathing or to the difficulty achieving satisfactory therapy with CPAP cannot be proven. These patients are complicated and there are obviously confounding factors; however, we believe that the distinctive aspects of their breathing patterns support our hypothesis. Recognition of airway occlusion, hypoxia, and breath-by-breath control of the ventilatory pattern is mainly the responsibility of the carotid bodies, especially during NREM sleep. 9, 10 The severity and unusual characteristics of the respiratory patterns ob- It can be seen that the most severe desaturations of Sao 2 occurred during NREM sleep. The earlier-than-normal REM onset and increased frequency of REM episodes can be associated with depression. Supplemental oxygen at 2 L/min was added at 3:00 am and maintained the Sao 2 near 94%; however, respiratory disturbances continued (bottom, C). Center, B: This 300-s sample corresponds with the area denoted as 2B on Figure  2 , top, A during NREM sleep and while breathing room air. The respiratory pattern is characteristic of Biot or ataxic breathing, the ventilatory equivalent of atrial fibrillation. Notice the irregularity of the respiratory rate, effort, and airflow associated with variable degrees of hypoxemia and that this pattern is present during NREM sleep. Bottom, C: This 300-s sample corresponds with the area denoted as 2C on Figure 2 , top, A during NREM sleep and while receiving supplemental oxygen at 2 L/min. Hypoxemia was corrected; however, ataxic breathing pattern persisted.
served during NREM sleep in these patients implicates carotid body dysfunction and/or disruption of processing of information from the carotid bodies secondary to opioid effects. Furthermore, we believe that the central defects reduce the effectiveness of nasal CPAP and lead to persistent hypoxemia and central apneas.
None of our patients presented with clinical conditions that would ordinarily be associated with central sleep apnea, such as congestive heart failure, primary neurologic diseases, or advanced age. 8 None were cigarette smokers, and none had clinical pulmonary disease or hypoxemia during wakefulness. Although these patients often present with routine clinical features of OSA syndrome, a major defect of respiratory control including blunted recognition of hypoxemia is obvious in most cases and is evident by the recurrent exceedingly prolonged obstructive hypopneas and periodic arterial oxygen desaturation or by sustained baseline hypoxemia during NREM sleep. The presence of airway obstruction may be very difficult to detect in some patients who appear to have predominant central events; however, our patients failed to respond or responded poorly to nasal CPAP. Furthermore, while we cannot exclude the possibility of drug interaction, it seems unlikely that the ataxic breathing patterns or the degree of respiratory suppression observed in these patients could have occurred without the more potent effects of opioids. For example, there may be an interaction with benzodiazepines or antidepressants 15, 16 ; however, we have not observed these types of breathing patterns in other patients receiving similar medications unless opioids were also present. Whether or not concurrent medications were partially contributory, the potential for adverse effects still exist because these medications are commonly used simultaneously in ordinary clinical circumstances.
All currently available opioids used for analgesia also suppress respiratory drive. The potential adverse effects of parenteral therapy used in the perioperative setting have been emphasized especially in patients with sleep apnea. [17] [18] [19] [20] It is widely believed that side effects from opioid therapy diminish with time and that analgesic tolerance may develop more rapidly than does respiratory tolerance. 4 However, investigations pertaining to the effects of long-term administration are scant. 21 To our knowledge, there have been no clinical sleep studies of patients with documented or suspected sleep-disordered breathing such as OSA receiving long-term opioid therapy. The majority of research concerned with the respiratory effects of opioids on respiration have been fixed on the results of parenteral administration in normal subjects during wakefulness. 22 We are aware of only two studies that have examined the effects of oral opioids on respiration during sleep. Robinson et al 23 examined the effects of a single dose of hydromorphone administered to healthy individuals, and there was no significant change in any measure of sleep-disordered breathing. Long-term use of methadone 24 has been associated with central apneas and lower baseline Sao 2 during sleep when compared to control subjects. However, ataxic breathing or Biot respiration has not been previously described in this setting but seems to be a particularly obvious characteristic in our population.
In summary, we have described three representative patients from our clinic with very unusual sleep-disordered breathing patterns in whom opioid therapy may have contributed to the pathogenesis of sleep-disordered breathing or complicated therapy. Ataxic breathing, unusually prolonged obstructive "hypopneas" with profound hypoxemia, and central apneas only during NREM sleep were characteristic, and nasal CPAP therapy without supplemental oxygen was consistently ineffective. There is potential for harm because patients with OSA syndrome continue to be underdiagnosed, 25, 26 while at the same time the use of oral opioids for chronic pain control increases. Furthermore, opioids could interfere with providing effective nasal CPAP therapy. Patients receiving long-term, long-acting opioids need to be screened and monitored for sleepdisordered breathing. Symptoms of persistent fatigue with or without other features of OSA should possibly trigger a careful investigation for sleep apnea. Further prospective studies of the effects of sustained-release opioids on respiration during sleep are urgently needed. Questions to be answered relate to the dose, duration, specific opioid, and associated comorbid factors including interaction with other medications such as benzodiazepines and antidepressants.
